


In the Claims:

1-15. (Canceled)


16. (Currently Amended) A compound of formula (I)



wherein

---- represents a single or a double bond;

R is a radical selected from:



in which  $R_1$  is halogen, cyano,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy, trifluoromethyl or trifluoromethoxy and  $p$  is zero or an integer from 1 to 3;

$R_2$  is hydrogen or  $C_{1-4}$  alkyl;

$R_3$  is hydrogen, hydroxy or  $C_{1-4}$  alkyl;

$R_4$  is hydrogen or  $R_4$  together with  $R_3$  is  $=O$  or  $=CH_2$ ;

$R_5$  is phenyl, naphthyl, a 9 to 10 membered fused bicyclic heterocyclic group or a 5 or 6 membered heteroaryl group, wherein said groups are optionally substituted by 1 to 3 groups independently selected from trifluoromethyl,  $C_{1-4}$  alkyl, hydroxy, cyano,  $C_{1-4}$  alkoxy, trifluoromethoxy, halogen or  $S(O)_q C_{1-4}$  alkyl;

$R_6$  and  $R_7$  independently are hydrogen, cyano,  $C_{1-4}$  alkyl;

$R_8$  is  $(CH_2)_r R_{10}$ ;

R<sub>9</sub> is hydrogen, halogen, C<sub>3-7</sub> cycloalkyl, hydroxy, nitro, cyano or C<sub>1-4</sub> alkyl optionally substituted by one or two groups selected from halogen, cyano, hydroxy or C<sub>1-4</sub> alkoxy;

R<sub>10</sub> is hydrogen or C<sub>3-7</sub> cycloalkyl;

n is [[1 or]] 2;


q is 0, 1 or 2;

r is 0 or an integer from 1 to 4;

or a pharmaceutically acceptable salt or a solvate thereof.

17. (Canceled).

18. (Previously Presented) A compound as claimed in claim 1 wherein R is:



wherein R<sub>1</sub> is halogen, C<sub>1-4</sub> alkyl, cyano, C<sub>1-4</sub> alkoxy, trifluoromethyl or trifluoromethoxy and p is zero or an integer from 1 to 3.

19. (Previously Presented) A compound as claimed in claim 1 wherein R<sub>5</sub> is phenyl or naphthyl optionally substituted by one or two groups selected from trifluoromethyl, cyano, C<sub>1-4</sub> alkyl or halogen.

20. (Previously Presented) A compound as claimed claim 1 wherein R<sub>8</sub> is (CH<sub>2</sub>)<sub>r</sub>R<sub>10</sub> wherein R<sub>10</sub> is hydrogen or C<sub>3-7</sub> cycloalkyl and r is 0 or 1.

21. (Previously Presented) A compound as claimed in claim 1, wherein R<sub>9</sub> is hydrogen or C<sub>1-4</sub> alkyl optionally substituted by one or two halogens.

22. (Currently Amended) A compound as claimed in claim 1 wherein:

R is phenyl substituted by a fluorine;

R<sub>2</sub>, R<sub>9</sub> and R<sub>4</sub> are each hydrogen;

R<sub>3</sub> is hydrogen, hydroxy or methyl, or R<sub>3</sub> together with R<sub>4</sub> is =O or =CH<sub>2</sub>;

R<sub>6</sub> and R<sub>7</sub> are independently hydrogen or methyl;

R<sub>5</sub> is phenyl or naphthyl optionally substituted by one or two groups

independently selected from cyano, methyl, chlorine, bromine or fluorine atom;  
and

R<sub>8</sub> is hydrogen, methyl or cyclopropylmethyl; ~~and~~

~~n is 2.~~

23. (Currently Amended) A compound selected from:

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-1,5-dihydro-  
2*H*-pyrrol-2-one;

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-  
dihydro-2*H*-pyrrol-2-one ;

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-1,5-dihydro-  
2*H*-pyrrol-2-one (Chain Enantiomer 1);

1-[(1*S*)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-1,5-  
dihydro-2*H*-pyrrol-2-one ;

1-[(3-Chloro-1-naphthalenyl)methyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-1,5-  
dihydro-2*H*-pyrrol-2-one;

4-({3-[4-(4-Fluorophenyl)-4-piperidinyl]-2-oxo-2,5-dihydro-1*H*-pyrrol-1-yl)methyl)-  
2-naphthalenecarbonitrile;

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-1,5-dihydro-  
2*H*-pyrrol-2-one (Chain Enantiomer 2);

1-[(1*R*)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-1,5-  
dihydro-2*H*-pyrrol-2-one;

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-  
dihydro-2*H*-pyrrol-2-one (Chain Enantiomer 1);

1-[(1*S*)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-  
piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one ;

1-[(3-Chloro-1-naphthalenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one;

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one (Chain Enantiomer 2);

1-[(1*R*)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one;

4-({3-[4-(4-Fluorophenyl)-1-methyl-4-piperidinyl]-2-oxo-2,5-dihydro-1*H*-pyrrol-1-yl)methyl)-2-naphthalenecarbonitrile;

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one hydrochloride (Chain Enantiomer 1);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one hydrochloride (Chain Enantiomer 1);

1-[(3-Chloro-1-naphthalenyl)methyl]-3-[1-(cyclopropylmethyl)-4-(4-fluorophenyl)-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one;

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone

1-[(1*S*)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 1);

1-[(1*S*)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone;

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 1 Chain Enantiomer 1);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 2 Chain Enantiomer 1);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 1 Chain Enantiomer 2);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 2 Chain Enantiomer 2);

4-({3-[4-(4-Fluorophenyl)-4-piperidinyl]-2-oxo-1-pyrrolidinyl)methyl)-2-naphthalenecarbonitrile (Enantiomer 1);

4-({3-[4-(4-Fluorophenyl)-4-piperidinyl]-2-oxo-1-pyrrolidinyl)methyl)-2-naphthalenecarbonitrile (Enantiomer 2);

7-Fluoro-4-({3-[4-(4-fluorophenyl)-4-piperidinyl]-2-oxo-1-pyrrolidinyl)methyl)-2-naphthalenecarbonitrile (Enantiomer 2);

6-Fluoro-4-({3-[4-(4-fluorophenyl)-4-piperidinyl]-2-oxo-1-pyrrolidinyl)methyl)-2-naphthalenecarbonitrile (Enantiomer 2);

7-Fluoro-4-({3-[4-(4-fluorophenyl)-4-piperidinyl]-2-oxo-1-pyrrolidinyl)methyl)-2-naphthalenecarbonitrile (Enantiomer 1);

6-Fluoro-4-({3-[4-(4-fluorophenyl)-4-piperidinyl]-2-oxo-1-pyrrolidinyl)methyl)-2-naphthalenecarbonitrile (Enantiomer 1);

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone;

1-[1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 2 Chain Enantiomer 1);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 1 Chain Enantiomer 1);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 2 Chain Enantiomer 1);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 1 Chain Enantiomer 2);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 2 Chain Enantiomer 2);

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Enantiomer 1);

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Enantiomer 2);

4-({3-[4-(4-Fluorophenyl)-1-methyl-4-piperidinyl]-2-oxo-1-pyrrolidinyl)methyl)-2-naphthalenecarbonitrile (Enantiomer 1);

4-({3-[4-(4-Fluorophenyl)-1-methyl-4-piperidinyl]-2-oxo-1-pyrrolidinyl)methyl)-2-naphthalenecarbonitrile (Enantiomer 2);

7-Fluoro-4-({3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-oxo-1-pyrrolidinyl)methyl)-2-naphthalenecarbonitrile (Enantiomer 2);

6-Fluoro-4-({3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-oxo-1-pyrrolidinyl)methyl)-2-naphthalenecarbonitrile;

7-Fluoro-4-({3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-oxo-1-pyrrolidinyl)methyl)-2-naphthalenecarbonitrile (Enantiomer 1);  
6-Fluoro-4-({3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-oxo-1-pyrrolidinyl)methyl)-2-naphthalenecarbonitrile (Enantiomer 1);  
1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1*H*-pyrrole-2,5-dione;  
1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-5-methylidene-1,5-dihydro-2*H*-pyrrol-2-one;  
and pharmaceutically acceptable salts or solvates thereof.

24. (Previously Presented) A compound according to claim 23 in amorphous or crystalline form.

25. (Previously Presented) A compound selected from:  
1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one;  
1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one hydrochloride;  
1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one fumarate;  
1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one citrate.

26. (Previously Presented) A compound according to claim 25 in crystalline form.

27. (Previously Presented) 1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one citrate.

28. (Previously Presented) 1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one.

29. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 1 in admixture with one or more pharmaceutically acceptable carriers or excipients.
30. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 25 in admixture with one or more pharmaceutically acceptable carriers or excipients.
31. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 28 in admixture with one or more pharmaceutically acceptable carriers or excipients.
32. - 37. (Canceled).
38. (Previously Presented) 1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-1,5-dihydro-2H-pyrrol-2-one or a pharmaceutically acceptable salt or a solvate thereof.
39. (Previously Presented) A hydrochloride salt of the compound according to claim 38.
40. (Previously Presented) A fumarate salt of the compound according to claim 38.
41. (Previously Presented) A citrate salt of the compound according to claim 38.
42. (Previously Presented) A citrate salt according to claim 41, having a crystal form with x-ray powder diffraction pattern with d spacings as follows:

Two theta (deg)	d-spacing (Angstroms)
7,1	12,5
10,6	8,4
11,6	7,7
11,9	7,4
14,0	6,3
14,5	6,1
16,0	5,5
16,8	5,3
17,6	5,0
18,5	4,8
19,5	4,6
19,9	4,5
20,6	4,3
21,2	4,2
21,8	4,1
22,4	4,0
23,1	3,9
23,6	3,8

Two theta (deg)	d-spacing (Angstroms)
24,0	3,7
24,9	3,6
25,5	3,5
26,4	3,4
28,1	3,2
29,1	3,1
29,7	3,0
32,9	2,7

43. (Previously Presented) A citrate salt according to claim 41, having a crystal form with x-ray powder diffraction pattern with d spacings as follows:

d spacing Angstroms	Two Theta (deg)
7,7	11,5
7,2	12,2
5,5	16,1
5,3	16,7
5,0	17,6
4,8	18,6
4,6	19,4
4,2	21,1
3,9	23,1
3,8	23,6
3,6	24,5



44. (Previously Presented) A crystalline hydrate of the compound according to claim 38.